Boston Scientific (NYSE:BSX) won pre-market approval from the FDA for its Epic self-expanding iliac stent.
The watchdog agency approved the device for treating de novo or restenotic symptomatic atherosclerotic lesions in the iliac arteries, according to agency documents released today.